NCT01274338 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 511
- group Id
- BG001
- value
- 636
- group Id
- BG002
- value
- 523
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1673
- units
- Participants
- groups
- description
- Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- Arm A (HIP)
- description
- Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- Arm B (HDI)
- description
- Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
- id
- BG002
- title
- Arm C (LIP)
- description
- Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
- id
- BG003
- title
- Arm D (HIP; Pediatric)
- description
- Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
- id
- BG004
- title
- Arm E (HDI; Pediatric)
- description
- Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
- id
- BG005
- title
- Arm F (LIP; Pediatric)
- description
- Total of all reporting groups
- id
- BG006
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 18
- upper Limit
- 60
- value
- 54
- group Id
- BG001
- lower Limit
- 18
- upper Limit
- 83
- value
- 54
- group Id
- BG002
- lower Limit
- 19
- upper Limit
- 80
- value
- 54
- group Id
- BG003
- lower Limit
- 15
- upper Limit
- 15
- value
- 15
- group Id
- BG004
- lower Limit
- 17
- upper Limit
- 17
- value
- 17
- group Id
- BG005
- lower Limit
- 17
- upper Limit
- 17
- value
- 17
- group Id
- BG006
- lower Limit
- 15
- upper Limit
- 83
- value
- 54
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 241
- group Id
- BG002
- value
- 195
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 607
- title
- Female
- measurements
- group Id
- BG000
- value
- 342
- group Id
- BG001
- value
- 395
- group Id
- BG002
- value
- 328
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1066
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 44
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 484
- group Id
- BG001
- value
- 591
- group Id
- BG002
- value
- 488
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1566
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 63
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 11
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 5
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 497
- group Id
- BG001
- value
- 620
- group Id
- BG002
- value
- 510
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1630
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 24
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- All randomized patients
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 511
- group Id
- BG001
- value
- 636
- group Id
- BG002
- value
- 523
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1673
- units
- Participants
- groups
- description
- Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
- id
- BG000
- title
- Arm A (HIP)
- description
- Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity.
- id
- BG001
- title
- Arm B (HDI)
- description
- Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
- id
- BG002
- title
- Arm C (LIP)
- description
- Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
- id
- BG003
- title
- Arm D (HIP; Pediatric)
- description
- Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
- id
- BG004
- title
- Arm E (HDI; Pediatric)
- description
- Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
- id
- BG005
- title
- Arm F (LIP; Pediatric)
- description
- Total of all reporting groups
- id
- BG006
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 18
- upper Limit
- 60
- value
- 54
- group Id
- BG001
- lower Limit
- 18
- upper Limit
- 83
- value
- 54
- group Id
- BG002
- lower Limit
- 19
- upper Limit
- 80
- value
- 54
- group Id
- BG003
- lower Limit
- 15
- upper Limit
- 15
- value
- 15
- group Id
- BG004
- lower Limit
- 17
- upper Limit
- 17
- value
- 17
- group Id
- BG005
- lower Limit
- 17
- upper Limit
- 17
- value
- 17
- group Id
- BG006
- lower Limit
- 15
- upper Limit
- 83
- value
- 54
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 241
- group Id
- BG002
- value
- 195
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 607
- title
- Female
- measurements
- group Id
- BG000
- value
- 342
- group Id
- BG001
- value
- 395
- group Id
- BG002
- value
- 328
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1066
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 44
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 484
- group Id
- BG001
- value
- 591
- group Id
- BG002
- value
- 488
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1566
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 63
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 11
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 5
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 497
- group Id
- BG001
- value
- 620
- group Id
- BG002
- value
- 510
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1630
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 24
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- All randomized patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle